Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

Janssen Research & Development, LLC clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
701
Shown on this page
12
Local recruiting
65
Top conditions
6

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Janssen Research & Development, LLC. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 1–12 of 701 matching trials for sponsor Janssen Research & Development, LLC.
Live ClinicalTrials.gov results.

Top conditions

Multiple Myeloma 23 Carcinoma, Non-Small-Cell Lung 11 Prostatic Neoplasms 10 Colitis, Ulcerative 9 Arthritis, Psoriatic 8 Crohn Disease 6

Top locations

New York, New York 90 Houston, Texas 62 Philadelphia, Pennsylvania 50 Nashville, Tennessee 49 Charlotte, North Carolina 47 Atlanta, Georgia 46

Top therapies

Amivantamab 18 Guselkumab 13 Teclistamab 13 Dexamethasone 12 Talquetamab 12 Daratumumab 11

Live official records

Open in full search
Recruiting Phase 1 Interventional

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157
View directory record Official record
Conditions
Neoplasms
Interventions
JNJ-88549968, Ruxolitinib, Momelotinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
17
States / cities
Duarte, California • Aurora, Colorado • Tampa, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 7:43 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

NCT03299049
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
1,049 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 7:43 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT04630028
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Ustekinumab Dose Based on BSA and Body Weight, Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 27, 2026, 7:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)

NCT07871435
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
GI-102, Pasritamig
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 27, 2026, 7:43 PM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

NCT04176718
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
Interventions
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Andrew Yee, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 27, 2026, 7:43 PM EDT
Recruiting Phase 3 Interventional

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

NCT07577843
View directory record Official record
Conditions
Crohn Disease
Interventions
JNJ-78934804, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
22
States / cities
Anaheim, California • Chula Vista, California • Los Alamitos, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 27, 2026, 7:43 PM EDT
Recruiting Phase 3 Interventional

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07577856
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
JNJ-78934804, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
24
States / cities
Anaheim, California • Chula Vista, California • Los Alamitos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 7:43 PM EDT
Recruiting Phase 2 Interventional

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

NCT07657312
View directory record Official record
Conditions
Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Naresh Bumma
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 27, 2026, 7:43 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

NCT05518149
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Aticaprant
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
87
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 27, 2026, 7:43 PM EDT
Recruiting Phase 4 Interventional

A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

NCT07654751
View directory record Official record
Conditions
Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic
Interventions
Breast Milk Sample Collection, Guselkumab
Procedure · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 7:43 PM EDT
Recruiting Early Phase 1 Interventional

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

NCT06398457
View directory record Official record
Conditions
Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
Interventions
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 7:43 PM EDT
Recruiting Phase 3 Interventional

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

NCT07573176
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
34
States / cities
Bryant, Arkansas • Bellflower, California • Glendale, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 7:43 PM EDT

About this Janssen Research & Development, LLC sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Janssen Research & Development, LLC is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Janssen Research & Development, LLC trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Janssen Research & Development, LLC.